Navigation Links
Rigel Announces Fourth Quarter and Year End 2011 Financial Results
Date:3/6/2012

010.  In June 2011, Rigel completed an underwritten public offering in which it sold 18,745,000 shares of its common stock pursuant to an effective registration statement at a price to the public of $8.00 per share. Rigel received net proceeds of approximately $140.5 million, after deducting underwriting discounts and commissions and offering expenses. Rigel expects to end 2012 with cash, cash equivalents and available for sale securities in excess of $140.0 million, which is expected to be sufficient to fund operations into 2014.

"During the past year, a number of Rigel's R&D programs have made significant strides, and we now have a broad and deep lineup of potential product candidates in our primary therapeutic areas of immunology and muscle disorders," said James M. Gower, chairman and chief executive officer of Rigel. He added, "In addition to our lead product, fostamatinib, which is in Phase 3 clinical trials with our partner AZ, our pipeline now includes three wholly-owned products currently in clinical studies and a queue of others projected to start first in human studies in 2013."

Pipeline/Program Update

As of March 2012, Rigel has eight novel small molecule programs in clinical or preclinical development, including Rigel's partner, AZ's Phase 3 clinical trial program (OSKIRA) with fostamatinib in patients with RA.   AZ has recently announced that it expects to file for a new drug application for fostamatinib with the U.S. Food and Drug Administration in the second half of 2013.  Rigel's seven other potential new product programs are the focus of Rigel's research and development teams and include:

  • R343, an inhaled SYK inhibitor for allergic asthma.   Rigel resumed responsibility for this program following closure of Pfizer Inc.'s allergy and respiratory development programs in 2011. Based on its mechanism of action, this inhaled SYK inhibitor is expected to provide a new treatment paradigm for the
    '/>"/>

    • SOURCE Rigel Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Rigel Announces Participation at Two Investor Conferences
    2. Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
    3. Rigel to Present at Oppenheimer Annual Healthcare Conference
    4. Rigel Announces Third Quarter 2011 Financial Results
    5. Rigel to Present at Two Upcoming Investor Conferences
    6. Rigel to Present at Wells Fargo Securities Healthcare Conference
    7. Rigel to Present at Jefferies Global Healthcare Conference
    8. Rigel Announces Pricing of Public Offering of Common Stock
    9. Rigel Announces Proposed Public Offering of Common Stock
    10. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
    11. Rigel Announces First Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
    (Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
    (Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies that ... that CEO Doug Godshall is scheduled ... 11:00 a.m. EDT on Monday, May 20, 2013.  The conference ... York Hotel. A live webcast of the Company,s ...
    Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
    ... , CARY, N.C., Nov. 20 Cornerstone Therapeutics Inc. ... on acquiring, developing and commercializing significant products primarily for ... had received a Warning Letter from the Food and ... tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) ...
    ... , HARRISBURG, Pa., Nov. 20 The Department ... priority groups that did not have previous access to the vaccine. , ... Friday,s clinic hours are from 2 p.m. to 8 p.m. Hours on ... Nov. 22, the clinics will operate from 2 p.m. to 8 p.m. ...
    Cached Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
    (Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
    (Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay ... latest edition of what is considered the "bible" of ... changes continues. "This is unprecedented, the amount of ... president-elect of the American Psychiatric Association (APA). "It,s been ... is. You have to evaluate it and then make ...
    (Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
    (Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
    (Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
    Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
    ... brain seen in people with Alzheimer's disease has been ... their cognitive abilities and become unusually forgetful. ,The ... who may develop Alzheimer's disease.Alzhiemer’s disease results in memory ... in the USA are estimated to suffer from this ...
    ... of Disease in Childhood recently published a study which proves ... hand-eye coordination of toddlers.// ,The trial was done ... fish oil/olive oil supplements from 20th week of their pregnancy ... and those who did not routinely eat more than two ...
    ... encephalopathy may need to get cooler at the top, to ... during birth. Such babies can now be helped with a ... damage. This product has been approved by the Food and ... device with the brand name of ‘Cool-Cap’ may be a ...
    ... the rules governing the private educational institutions in the ... ,The state cabinet decided to adopt the new rules ... an official said here. ,The school managements ... students, pay prescribed and timely salaries to teaching and ...
    ... study has indicated that inflammatory bowel disease in women could ... times.// , ,Diseases such as Crohn's disease and ulcerative ... babies or premature babies. Yet, the 'silver lining' exists in ... certainly reduced the risks. ,The St. Mary's ...
    ... January issue of the medical journal Otolaryngology- Head and Neck ... permanent long-term hearing loss that can be caused by exposure ... measured the impact of “impulse noise” (short bursts of acoustic ... by using short-term exposure to the impulse noise generated by ...
    Cached Medicine News:Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
    Disposable tracheostomy care tray....
    Disposable tracheostomy care tray....
    ... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
    ... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
    Medicine Products: